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Abstract. Evidence on the impact of using diagnostic tests in community case management of febrile children is
limited. This effectiveness trial conducted in Burkina Faso, Ghana, and Uganda, compared a diagnostic and treatment
package for malaria and pneumonia with presumptive treatment with anti-malarial drugs; artemisinin combination
therapy (ACT). We enrolled 4,216 febrile children between 4 and 59 months of age in 2009–2010. Compliance with the
malaria rapid diagnostic test (RDT) results was high in the intervention arm across the three countries, with only 4.9%
(17 of 344) of RDT-negative children prescribed an ACT. Antibiotic overuse was more common: 0.9% (4 of 446) in
Uganda, 38.5% (114 of 296) in Burkina Faso, and 44.6% (197 of 442) in Ghana. Fever clearance was high in both
intervention and control arms at both Day 3 (97.8% versus 96.9%, P = 0.17) and Day 7 (99.2% versus 98.8%, P = 0.17).
The use of diagnostic tests limits overuse of ACTs. Its impact on antibiotic overuse and on fever clearance is uncertain.
INTRODUCTION
Malaria and pneumonia are leading causes of morbidity
and mortality among under-fives in sub-Saharan Africa,1–3
despite the availability of cost-effective interventions for both
conditions. Community case management of malaria and pneu-
monia have both been shown to reduce under-five mortality,4,5
and both strategies are recommended by the World Health
Organization (WHO).6–8
Parasitological confirmation before administration of anti-
malarial treatment has recently been recommended by WHO
for everyone presenting with symptoms compatible with
malaria at all levels of the health system.9 Such confirmation
is increasingly important in the context of declining malaria
transmission, when a decreasing proportion of fever cases
is likely to be caused by malaria.10 Furthermore, given the
overlap in symptoms between malaria and pneumonia,11 the
WHO and the United Nations Children Fund (UNICEF) now
recommend integrated community case management (iCCM)
of malaria and pneumonia in endemic areas in low- and middle-
income countries.8
Rapid diagnostic tests (RDTs) for malaria are now available
with sensitivities comparable to routinemicroscopy in detecting
malaria12–14 and offer a practical means15,16 to improve diag-
nosis and quality of care of febrile children in malarious areas.
Several studies have shown that community health workers
(CHWs) can use RDTs safely and effectively.14,17–20
Increased respiratory rate is one of the most specific symp-
toms of pneumonia21–23 and respiratory rate timers (RRTs)24
have been recommended by WHO and UNICEF as a diag-
nostic tool for pneumonia, with studies19,25,26 showing that
CHWs can be successfully trained to use them.
We designed an integrated diagnostic and treatment package
for malaria and pneumonia, which involves trained CHWs,
equipped withRDTs and RRTs and supplied with anti-malarial
drugs (artemisinin based combination therapy (ACTs)) and
antibiotics, administering treatments based on the results of the
two tests. We report here an effectiveness trial conducted in
three African countries, Burkina Faso, Ghana, and Uganda,
with differing national health systems. We evaluated the effect
of the package on the clinical outcome of febrile episodes in
children and on the use of anti-malarial and antibiotic drugs.
MATERIALS ANDMETHODS
Study areas and populations. We report this evaluation
using the CONSORT statement extension to cluster ran-
domized trials.27 The evaluation was conducted in Burkina
Faso, Ghana, and Uganda, in the districts of Sapone´, Kassena
Nankana, and Iganga, respectively. Sapone´ and Kassena
Nankana are situated in the Sudan-Sahelian eco-climatic
zone, with a seasonal malaria transmission pattern. Iganga is
situated in South Eastern Uganda with an equatorial climate
and minimal seasonal variation in malaria transmission.28 In
Sapone´, malaria transmission is markedly seasonal, with most
transmission occurring during the rainy season, and with an
entomological inoculation rate (EIR) ranging from 50 to
200 infective bites/person/year. Plasmodium falciparum is the
predominant malaria parasite accounting for more than 95%
of infections in children < 5 years of age. The malaria burden
is heaviest among children < 5 years of age, who experience
an average of two clinical malaria episodes every transmission
season. Iganga district has year-round malaria transmission,
and over 90% of malaria cases are caused by P. falciparum
infection.28 Transmission peaks are seen following the rains:
i.e., April to June and September to December.29 The annual
EIR is not known, but is reported to be > 500 infective bites/
person/year in the neighboring district of Tororo.30 In Kassena
Nankana, malaria transmission occurs during most months of
the year; however, there is a distinct seasonal pattern with the
peak of transmission coinciding with the period of the major
rains (May–October) and the dry season (November–April)
seeing very low rates of malaria infection. Transmission has
been estimated to be 418 infective bites/person/year.31–33
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Data were collected in Burkina Faso from August 2009 to
June 2010, in Ghana from April 2009 to February 2010, and in
Uganda from October 2009 to October 2010. The sites were
selected by an advisory committee from those who responded
to a call by TDR in 2006. Some variations in the methodology
were unavoidable, because in each case the specific national
health framework was followed. Because of varying sample
size per country, and the ease of access to nationally available
supplies, the studies started and ended at different times.
Twelve villages participated in the study in Burkina Faso,
16 in Ghana, and 14 in Uganda. In Burkina Faso, the 12 vil-
lages were selected from two community clinic catchment
areas within the Sapone´ Health District with an estimated
total population of 9,000. The 16 villages selected in the
Kassena-Nankana districts were drawn from 47 villages with
a total population of 150,000 under continuous demographic
surveillance. The 14 villages in Iganga were all drawn from
Namungalwe sub-county, which has a population of ~38,100
in 19 villages. Malaria, pneumonia, and diarrheal diseases are
the leading causes of ill-health among children 1–59 months
of age in the three study areas.34–36
We included children 6–59 months of age (with the excep-
tion of Uganda where the lower limit was 4 months in line
with national guidelines on the use of ACTs in children37,38)
with measured fever or history of fever (last 24 hours), who
presented to a CHW. Exclusion criteria included severe
illness (according to Integrated Management of Childhood
Illness [IMCI] guidelines), known chronic disease, reported
anti-malarial or antibiotic treatment in the previous 2 weeks,
or known sensitivity to the study medications.
Study design. The study was designed to assess the effect
of the use of a diagnostic and treatment package for iCCM,
comprising RDTs and ACTs for malaria, RRTs and antibi-
otics for pneumonia, on recovery from fever, and the rational
use of medicines.
We performed an open, cluster randomized two-arm trial in
the three countries. Clusters were the villages (catchment popu-
lations) of individual CHWs.Within the study areas we excluded,
for ethical reasons, clusters that were more than 5 km from a
designated health facility where CHWs referred cases for special
care to minimize non-completion of referral because of distance.
A cluster randomized design was chosen over an individually
randomized design to reduce contamination, facilitate super-
vision, reduce costs, and to ensure that the CHWs maintained
the correct treatments based on the tests in the intervention
arm and the presumptive treatment in the control arm.
In the intervention arm, CHWs assessed children with acute
febrile illness for malaria using RDTs, and for pneumonia by
counting their respiratory rate with RRTs. Treatment was
then provided on the basis of the test results. Children with a
positive RDT received artemether-lumefantrine in Burkina
Faso and Uganda, and artesunate-amodiaquine in Ghana.
Children with a high respiratory rate received amoxicillin in
Ghana and Uganda, and cotrimoxazole in Burkina Faso. The
criterion for antibiotic administration was the presence of a
high respiratory rate, regardless of the presence of cough or
difficult breathing, in contrast to WHO guidelines.39 Addi-
tionally, paracetamol (PCT) was provided to all children in
whom both RDT and RRT were negative, and to children
with an axillary temperature > 38.5°C.
In the control arm, all febrile children received ACTs based
on a presumptive diagnosis of malaria as provided for in the
current IMCI guidelines. In line with the protocol, CHWs
in Burkina Faso and Uganda were not provided with antibi-
otics. In Ghana, in line with existing practice, CHWs in the
control clusters were also supplied with amoxicillin that they
could provide to children based on clinical judgment. Antibi-
otics and anti-malarial drugs were provided as 3-day treatment
courses, whereas PCTwas provided for 2 days, so that it did not
interfere with the fever assessment on Day 3. The first dose of
all treatments was administered under the supervision of the
CHW, and if the child vomited within 30 minutes they were
given another dose. The dosing schedule was explained to care-
giverswho thenadministered the remaining treatments at home.
Malaria RDTs used. First Sign Malaria Pf Card Test
(Unimed International, Inc., Santa Clara, CA), Paracheck
Pf Rapid test for P. falciparum Malaria (Device) (Orchid
Biomedical System, Goa, India), and ICT Malaria Pf Cassette
test (ICT Diagnostics South Africa) were used in Burkina
Faso, Ghana, and Uganda, respectively. First Sign, Paracheck,
and ICT have panel detection scores (PDS) at parasite densi-
ties from 2,000 parasites/mL of 86.1%, 97.5%, and 97.5%,
respectively, and PDSs at parasites densities of 200 parasites/
mL of 31.7%, 54.4%, and 82.3%, respectively.40
Drugs used in the study. The ACTs used in the study were
Coartem manufactured by Novartis Pharma in Burkina Faso,
Acumal (artesunate-amodiaquine) manufactured by JCPL
Pharma PVT Ltd., India in Ghana, and Coartem manu-
factured by Novartis Pharmaceuticals Corporation Suffern,
New York in Uganda. Antibiotics used in the study were
cotrimoxazole in Burkina Faso manufactured by Medicamen
Biotech Ltd., India, Kinamox (amoxicillin) in Ghana manu-
factured by Kinapharma Ltd., and in Uganda amoxicillin
manufactured by Zhangjiakou Shengda Pharmaceutical Co.
Ltd., China (re-packed by Kampala Pharmaceutical Indus-
tries, 1996 Ltd.).
Paracetamol used in the study was manufactured by Laborate
Pharmaceutical (India) for Burkina Faso, Kinapharma Ltd.
for Ghana, and Kampala Pharmaceutical Industries (1996)
Ltd. for Uganda.
Community health workers. A total of 57 CHWs were
recruited (13 in Burkina Faso, 16 in Ghana, and 28 in Uganda),
half of whom were randomized to the intervention arm. The
CHWs were selected by their respective community, based
on minimum criteria that included the ability to read and
write clearly so that they would be able to complete the study
Case Report form (CRF). In Burkina Faso new CHWs
were selected, whereas in Uganda existing CHWs previously
trained to provide anti-malarial drugs in the community as
part of the community case management were used. In Ghana,
existing community health nurses (living within the commu-
nity and hired and trained by the Ghana Health Service to
provide basic services) were used.
Sample size. The estimated sample size for the study was
4,360 febrile children between 4 and 59 months of age, with
Burkina Faso and Ghana contributing 1,200 each, and Uganda
1,960. The sample size was estimated using the simplified
formula by Hayes and Bennett41 for cluster randomized trials,
with a power of 80% to detect an absolute difference in fever
clearance 72 hours after initiation of treatment of 10% (85%
against 75%) between the two arms with a two-sided alpha
of 0.05. The estimation took seasonality into account, and
accounted for loss to follow-up. We assumed a coefficient of
variation between clusters of 0.12.
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Training. The CHWs were taught how to take a history,
recognize clinical features of uncomplicated malaria, and signs
of severe illness requiring referral; preparation of thick blood
films for malaria microscopy; the use of classification and
treatment algorithms for malaria and pneumonia (interven-
tion arm only); use of simple dosing guidelines based on
age for ACTs and PCT; managing drug supplies; obtaining
informed consent; and completing CRFs including documen-
tation of reported signs and symptoms, physical examination
results, and medications administered to the child. In cases
where informed consent was declined, the child received stan-
dard presumptive management of fever with an ACT.
In addition, CHWs in the intervention arm were taught
the clinical features of non-severe pneumonia; use of malaria
RDTs; infection control measures; how to count respiratory
rate; and the use of simple dosing guidelines based on age
for antibiotics.
There was interactive training consisting of oral presentations,
discussions, role play, and supervised hands-on practice for all
the study CHWs. At the end of the training, facilitators assessed
the competency of the CHWs to follow the algorithm, complete
study forms, and for CHWs in the intervention arm the appro-
priate use of RDTs and RRTs, as reported elsewhere.19
At the health facility level, health personnel were oriented
on the treatment strategies in the two arms, and received
refresher training on IMCI. These staff provided care to chil-
dren referred from the study and provided supportive super-
vision to the CHWs.
Quality assurance plan. The CHWs were supervised weekly
by field supervisors to detect and correct any deviations from
the protocol. During these visits, the following were mon-
itored: completeness of data captured in the CRFs, respect
of inclusion/exclusion criteria, drug administration, drug and
RDT storage conditions, and assessment and follow-up of
enrolled children.
At each supervisory visit three samples of RDTs were collected
from the batch in use. The RDT samples were tested against a
sample of blood confirmed positive by microscopy to ensure
the RDTs were still functioning with adequate sensitivity.42
At the end of each month all CHWs attended a review
meeting at the health center at which the assessment, treat-
ment, and follow-up algorithms were reviewed, and problem
areas were identified and discussed. The CHWs brought
their registers and CRFs. The CHWs identified as having
problems with a particular part of the algorithm were fol-
lowed up and were provided with support and retraining by
the study team. The accuracy of CHWs in performing the
RDTs was assessed as part of each supervisory visit. When
there were no patients at the time of the visit, CHWs were
asked to demonstrate how they perform the procedure,
including how they do the finger prick and how they read the
RDT result. The CHWs were observed and reminded to per-
form the RDT in a well-lighted place.
Refresher training was provided to the health facility micros-
copists on malaria microscopy before enrollment started.
Ten slides per month were selected for quality control (5 low
density and 5 negative slides) using a random number system
recommended by WHO43 and sent to a reference laboratory
for rereading on a “blinded” basis.
Data collection methods. All children who were tested for
malaria on Day 0 also had a thick blood film prepared by the
CHWs. The blood films were collected within 24 hours in all
three sites by a fieldwork supervisor with a motorbike. Blood
films were stained with 10% Giemsa stain for 10–15 minutes
and screened microscopically under a +100 oil immersion
lens using a light microscope by a microscopist trained by the
study teams and based at the referral center. A blood slide
was taken at Day 0 in the control arm to enable a comparison
of the prevalence of malaria in the two arms (in Uganda this
was only done in a sub-sample of enrolled children across
both dry and rainy seasons).
The number of parasites present per white blood cell was
counted, and the figure multiplied by 8,000 (an average white
blood cell count per mL) to give the parasite density.44 Slides
were double read, and when there was a discrepancy between
the two readings the slide was read again by an experienced/
senior microscopist who was independent of this study and
whose reading was considered final. The microscopy results
were used to establish the accuracy of the RDTs when used
in the communities. Children with a negative RDT, but with
a positive slide reading were traced at home and treated
with ACTs. All patient data were recorded on CRFs at all
three sites.
Patient management and follow-up. The CHWs reviewed
children and completed the CRF on Days 0, 3, 7, and on
unscheduled visit days. A review on Day 3 determined if a
child had recovered from fever (temperature below 37.5°C as
measured by a digital thermometer). Children in either arm
who had not recovered were referred to a designated health
center. All children not referred at Day 3 (clinically recov-
ered) were reviewed on Day 7, and any fever relapse cases
Figure 1. Study profile.
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were referred to the health center. All children referred
(Day 3 or 7) were examined by a trained project nurse, and
managed according to IMCI guidelines. Children who did not
come for scheduled visits were traced and assessed at home.
Study outcomes. The primary outcome was resolution of
fever at Day 3, whereas resolution of fever at Day 7, and the use
of anti-malarial and antibiotic drugs were secondary outcomes.
Outcomes were measured and analyzed at the individual level.
Data analyses.Data were entered into microcomputers and
analyzed using Epi-Info 6.0 (CDC, Atlanta, GA) and STATA
9.0 (College Station, TX). We compared proportions of the
study outcomes between the two groups. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated using
random effects logistic regression analysis with the treatment
arm and country as fixed effects, and cluster as a random
effect. Analysis was by intention-to-treat.
Ethical approval. Ethical approval for these studies was
granted by the WHO Ethics Review Committee and by the
appropriate national and Institutional Ethical Review Boards
of each participating country. Approval was obtained from
district, local, and community leaders as well as household
heads. Informed consent was obtained from caregivers of
children who participated in the studies. The WHO TDR
project numbers are A60486 for Burkina Faso, A60490 for
Ghana, and A60487 for Uganda. The trial was registered
online at http://register.clinicaltrials.gov with the registration
number NCT00720811.
RESULTS
Baseline characteristics. Overall, 4,216 children between
4 and 59 months of age were enrolled in Burkina Faso, Ghana,
and Uganda. The number of children enrolled in intervention
and control arms respectively were 525 and 576 in Burkina Faso,
584 and 591 in Ghana, and 975 and 965 in Uganda (Figure 1).
With the exception of reported cough, baseline characteristics
were comparable across the two arms (Table 1). In total,
64.5% (2,691 of 4,216) had temperatures ³ 37.5°C at enroll-
ment and 69.5% (2,729 of 3,925) had microscopically con-
firmed malaria.† The RDT positivity rate was 74.5% (391 of
525) in Burkina Faso (Table 2A), 84.2% (492 of 584) in Ghana
(Table 2B), and 87.9% (857 of 975) in Uganda (Table 2C).
Use of medicines. Use of medicines by assessment classifi-
cation is summarized by country in Table 2A–C. In the inter-
vention clusters, there was good compliance with RDT results
by CHWs across the three countries with minimal overuse of
ACTs. Only 1 case out of 1,740 RDT-positive children did
not receive an ACT, whereas only 4.9% (17 of 344) of RDT-
negative children were prescribed an ACT.
With regard to antibiotics, there were varying degrees of
overuse (prescription to a child with a normal respiratory
rate) in Burkina Faso, Ghana, and Uganda, with 38.5% (114
of 296), 44.6% (197 of 442), and 0.9% (4 of 446) of children
with a normal respiratory rate receiving an antibiotic, respec-
tively. Conversely, some children with high respiratory rates
did not receive an antibiotic: 13.5% (31 of 29) in Burkina
Faso, 27.5% (39 of 142) in Ghana, and 1.7% (9 of 529) in
Uganda. Among children with high respiratory rates, we ana-
lyzed data within the subgroup that also had a cough; 16% (20
of 125) in Burkina Faso, 17.9% (7 of 39) in Ghana, and 0.9%
(3 of 337) in Uganda of these children did not receive an
antibiotic. The overall rate of antibiotic underuse in this sub-
group was 6.0% (30 of 501).
In the control clusters, ACTs were given to all children in
all countries, leading to a potential unnecessary prescription
of ACTs in 25.6%, 15.8%, and 12.1% of cases in Burkina
Faso, Ghana, and Uganda, respectively (assuming a similar
proportion of RDT negative cases in the control and interven-
tion clusters). In Ghana (where antibiotics were available in
control clusters as well) 51.4% (300 of 584) of all children
were prescribed antibiotics in the intervention clusters com-
pared with 64.3% (380 of 591) in the control clusters (OR 1.7,
1.34–2.17; P < 0.001), suggesting less overprescription of anti-
biotics in the intervention arm.
Impact on fever clearance. Fever clearance results are sum-
marized in Table 3. There were high fever clearance rates
across the countries and arms. Fever clearance rates at Day 3
and Day 7 were 97.8% (95% CI 97.0, 98.7) and 99.2% (95%
CI 98.7, 99.8) in intervention clusters, and 96.9% (95% CI
96.1, 97.6) and 98.8% (95% CI 98.3, 99.3) in control clusters.
The estimated ORs for failure to clear fever (intervention
versus control) were 0.69 (95% CI 0.41, 1.16; P = 0.17) at
Day 3 and 0.62 (95% CI 0.32, 1.22; P = 0.17) at Day 7.
A subgroup analysis was done to explore if the use of anti-
biotics in the control arm in Ghana may have diluted the
effect of the intervention, with Ghana data excluded. Fever
clearance was marginally better in the intervention arm at
97.7% (95% CI 96.8, 98.6: 1,431 of 1,465) compared with
†Blood smear for microscopy done in only a sub-sample of children
in the control arm in Uganda.
Table 1
Baseline characteristics of children at enrollment
Burkina Faso Ghana Uganda
Intervention Control Intervention Control Intervention Control
Number of children enrolled 525 576 584 591 975 965
Number (%) with measured
temperature ³ 37.5
436 (83.0%) 457 (79.3%) 351 (60.1%) 372 (62.9%) 563 (57.7%) 512 (53.1%)
Mean age (in months) 28.7 30.3 24.6 26.0 27.8 27.3
Number (%) of females 277 (52.8%) 276 (47.9%) 277 (47.4%) 317 (53.6%) 451 (46.3%) 478 (49.5%)
P. f. asexual parasitemia prevalence
(by microscopy)
284 (54.1%) 313 (54.3%) 439 (75.2%) 435 (73.6%) 783 (80.3%) 475/674* (70.5%)
Geometric mean parasite density
in positives
11,841 10,505 15,320 12,350 7,663 7,318
Number (%) of children with cough 252 (48.0%) 241 (41.8%) 123 (21.1%) 226 (38.2%) 555 (56.9%) –
Number (%) of children with diarrhea 134 (25.5%) 154 (26.7%) 208 (35.6%) 208 (35.2%) – –
*Blood smear for microscopy done in only a sub-sample of children in the control arm in Uganda.
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96.2% (95% CI 95.0, 97.3: 1,464 of 1,522) in the control arm at
Day 3, with a 41% reduction in odds of having fever at Day 3
(OR = 0.59, 95% CI 0.38–0.93). At Day 7, fever clearance was
99.4% in the intervention arm (95% CI 98.8, 99.99) compared
with 99.0% (95% CI 98.7, 99.4) in the control arm (OR = 0.64,
95% CI 0.28, 1.49).
Although no formal pharmacovigilance system had been
put into place, there were no passive reports of severe adverse
events or deaths at any of the three sites.
DISCUSSION
We performed an effectiveness trial in three countries, exam-
ining the effects on fever clearance and rational use of medi-
cines of a diagnostic and treatment package, comprising RDTs
and ACTs for malaria, respiratory rate (RR) timers, and anti-
biotics for pneumonia, implemented at the community level to
treat children < 5 years of age with fever episodes. In each
country, we adopted a pragmatic approach, following existing
Table 2C
Assessment classification and treatment in Uganda
Number (%) of children treated with
Number (%) of children
by assessment classification
ACT+; AB+;
PCT± (A)
ACT+; AB−;
PCT± (B)
ACT−; AB+;
PCT± (C)
ACT−; AB−;
PCT+ (D)
Intervention clusters
Children with positive RDT and high RR (1) 459 (47.1) 449 (97.8) 9 (2.0) 1 (0.2) 0 (0.0)
Children with positive RDT, high RR and coughj (2) 286 (29.3) 282 (98.6) 3 (1.0) 1 (0.3) 0 (0.0)
Children with positive RDT and normal RR (3) 398 (40.9) 4 (1.0) 394 (99.0) 0 (0.0) 0 (0.0)
Children with negative RDT and high RR (4) 70 (7.2) 2 (2.9) 0 (0.0) 68 (97.1) 0 (0.0)
Children with negative RDT, high RR and coughj (5) 51 (5.2) 2 (3.9) 0 (0.0) 49 (96.1) 0 (0.0)
Children with negative RDT and normal RR (6) 48 (4.9) 0 (0.0) 7 (14.6) 0 (0.0) 41 (85.4)
Total 975 455 (46.7) 410 (42.1) 69 (7.1) 41 (4.2)
Control clusters
Total 965 0 (0.0) 965 (100.0) 0 (0.0) 0 (0.0)
N.B: Cells shaded gray represent correct treatment of the row.
The rows with the symbol j at the end of the row title are a subset of the row just above them. The numbers in the row cells do not count in the respective column totals.
ACT = artemisinin based combination therapy; AB = antibiotic; PCT = paracetamol; RDT = rapid diagnostic test; RR = respiratory rate.
Table 2B
Assessment classification and treatment in Ghana
Number (%) of children treated with
Number (%) of children
by assessment classification
ACT+; AB+;
PCT± (A)
ACT+; AB−;
PCT± (B)
ACT−; AB+;
PCT± (C)
ACT−; AB−;
PCT+ (D)
Intervention clusters
Children with positive RDT and high RR (1) 130 (22.3) 92 (70.8) 38 (29.2) 0 (0.0) 0 (0.0)
Children with positive RDT, high RR and coughj (2) 32 (5.5) 25 (78.1) 7 (21.9) 0 (0.0) 0 (0.0)
Children with positive RDT and normal RR (3) 362 (62) 144 (39.8) 218 (60.2) 0 (0.0) 0 (0.0)
Children with negative RDT and high RR (4) 12 (2.1) 0 (0.0) 1 (8.3) 11 (91.7) 0 (0.0)
Children with negative RDT, high RR and coughj (5) 7 (1.2) 0 (0.0) 0 (0.0) 7 (100) 0 (0.0)
Children with negative RDT and normal RR (6) 80 (13.4) 0 (0.0) 2 (2.5) 53 (66.3) 25 (31.3)
Total 584 236 (40.4) 259 (44.3) 64 (11) 25 (4.3)
Control clusters
Total 591 360 (60.9) 203 (34.4) 20 (3.4) 8 (1.4)
N.B: Cells shaded gray represent correct treatment of the row.
The rows with the symbol j at the end of the row title are a subset of the row just above them. The numbers in the row cells do not count in the respective column totals.
ACT = artemisinin based combination therapy; AB = antibiotic; PCT = paracetamol; RDT = rapid diagnostic test; RR = respiratory rate.
Table 2A
Assessment classification and treatment in Burkina Faso
Number (%) of children treated with
Number (%) of children
by assessment classification
ACT+; AB+;
PCT± (A)
ACT+; AB−;
PCT± (B)
ACT−; AB+;
PCT± (C)
ACT−; AB−;
PCT+ (D)
Intervention clusters
Children with positive RDT and high RR (1) 173* (32.9) 141 (81.5) 31 (17.9) 0 (0.0) 0 (0.0)
Children with positive RDT, high RR, and coughj (2) 90 (17.1) 70 (77.8) 20 (22.2) 0 (0.0) 0 (0.0)
Children*with positive RDT and normal RR (3) 218* (41.5) 75 (34.4) 141 (64.7) 0 (0.0) 0 (0.0)
Children with negative RDT and high RR (4) 56* (10.7) 3 (5.4) 0 (0.0) 37 (66) 0 (0.0)
Children with negative RDT, high RR and coughj (5) 35 (6.7) 2 (5.7) 0 (0.0) 33 (94.3) 0 (0.0)
Children with negative RDT and normal RR (6) 78* (14.9) 2 (2.6) 0 (0.0) 37 (56.4) 26 (33.3)
Total 525 221 (42.1) 172 (32.8) 74 (14.1) 26 (5.0)
Control clusters
Total 576 0 575 (99.8) 0 0
*Row data has missing records on treatment given.
N.B: Cells shaded gray represent correct treatment of the row.
The rows with the symbol j at the end of the row title are a subset of the row just above them. The numbers in the row cells do not count in the respective column totals.
ACT = artemisinin based combination therapy; AB = antibiotic; PCT = paracetamol; RDT = rapid diagnostic test; RR = respiratory rate.
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national policies. This resulted in some variations in what was
actually done in each country. The package led to a clear
improvement in the appropriate use of ACTs, and in Ghana, the
only site in which antibiotics were available in the control arm,
to fewer prescriptions of antibiotics. The vast majority of chil-
dren recovered from fever in both the intervention and control
groups, and no effect of the intervention on the clinical outcome
(recovery from fever) were detected. The microscopy positivity
rates reported from the three sites (54–80%) are not for the
general population, but for children who had been sick and were
taken to CHWs for care. These rates are much higher than what
would have been expected in a population-based sample.28,32
Inappropriate use of ACTs is a major concern, because it may
lead to the development of resistance to these highly effective
drugs.45 The potential for misuse of ACTs could be particu-
larly high at the community level, where ACTs are distributed
by non-professional staff.46,47 The latest WHO malaria treat-
ment guidelines9 recommend parasitological confirmation before
administering anti-malarial drugs to a patient presenting with
fever in all areas, including highly malaria-endemic settings. The
shift from symptom-based to RDT-based treatment with ACTs
has major implications. It limits the over-diagnosis of malaria
and thus the inappropriate use of ACTs and expenditure,48 and
reduces missed diagnosis of other causes of fever49,50 at a time
when a declining proportion of fevers in Africa are attributable
to malaria.10 Administering ACTs only to patients with a posi-
tive RDT has led to dramatic reductions in the use of ACTs in
Cambodia,18 mainlandTanzania,51 and Zanzibar.52 Nevertheless,
in some health facility settings substantial proportions of patients
with negative test results were reported to receive ACTs,53–56
although improvements in adherence to treatment guidelines
were achieved after intensive training in some cases.51,57
Poor adherence to RDT results has also been reported
when febrile episodes are managed at the community level
by CHWs, with up to 58% of patients with a negative RDT
result being treated with an antimalarial.58 Poor compliance
with referral advice by patients with fever but with a negative
RDT result has also been reported.59 It is noteworthy that
in both these studies there was no alternative diagnostic test,
nor treatment of RDT-negative patients. However, very high
levels of appropriate prescription of ACTs after rapid malaria
testing were achieved in Chikankata, Zambia in a program in
which febrile children were assessed for pneumonia, and anti-
biotic treatment was provided as appropriate25; similar find-
ings were reported more recently in another study in Zambia
that used an intensive training and supervision model.60
The results of our study in three sub-Saharan African coun-
tries, conducted with a similar design to the one in Chikankata,
confirm that inappropriate use of ACTs is extremely rare
(< 5% of cases) when alternative diagnostic tests and treat-
ment of other conditions are provided to patients with nega-
tive RDT results (in our study children with fever and a
negative RDT were prescribed antibiotic treatment if there
were signs of pneumonia, and PCT if there were none). On
the contrary, when anti-malarial treatment is administered
to all febrile children, without prior parasitological confir-
mation, as in the control clusters of our study, an important
proportion of cases are treated with ACTs unnecessarily. This
study was conducted in areas of high malaria prevalence, con-
firmed both by microscopic examination and RDT (Tables 1
and 2). It is important to note that the use of RDTs to guide
treatment decisions in these high transmission settings resulted
in substantial overprescription of ACTs, compared with treat-
ment based on the results of blood slide microscopy. Nonethe-
less, based on the proportion of negative RDT results in the
intervention clusters of the study sites, the proportion of unnec-
essary use of ACTs was estimated to vary between 12% and
26% across the three sites. This finding has public health impli-
cations, suggesting that a disease management approach based
on a diagnostic and treatment package improves the appropri-
ate use of ACTs, and provides alternative treatment of other
causes of febrile illness.
Inappropriate use (non-compliance with study guidelines)
of antibiotics was high in two study sites. More than a third
of children with a normal RR received antibiotic treatment
in Ghana and Burkina Faso, whereas 27% and 14% of chil-
dren with a high RR did not receive any antibiotics in the
two countries, respectively. In Ghana, however, where CHWs
could prescribe antibiotics in control clusters based on their
clinical judgment, 64.3% of children were treated with antibi-
otics in control clusters compared with 51.4% in interven-
tion clusters. In this study, we used only a high respiratory
rate as the criterion for antibiotic use, whereas the WHO39
recommends the presence of cough or difficulty breathing
together with high respiratory rate as the criteria. This is a
limitation of this study, and fewer children would have been
treated with antibiotics under WHO guidelines than were
treated using a criterion of rapid breathing alone. Overuse
of antibiotics is a well-known phenomenon at all levels of the
health system in low-, middle-, and high-income countries, as
reported by the WHO,61 and has been recently reported to be
aggravated by the introduction of RDT in the decision algo-
rithm.51 In Uganda, over- or under-prescription of antibiotics
was rare, accounting for only 0.9% and 1.7% of cases. This dif-
ference between Uganda and the other sites may be explained
by the more intensive supervision program of the CHWs, and
Table 3
Fever persistence on study Days 3 and 7 after the onset of treatment
Cluster
# of ch. with Temp ³ 37.5 and/or
reported hot body at D0
# of ch. seen
at D3
# of ch. with Temp ³ 37.5
at D3 (% of ch. Seen at D3)
#. of ch. seen
at D7
# of ch. with Temp ³ 37.5
at D7 (% of ch. Seen at D7)
Intervention clusters
Burkina Faso 525 (436) 507 11 (2.2) 485 2 (0.4)
Ghana 584 (351) 578 10 (1.7) 561 6 (1.1)
Uganda 975 (563) 958 23 (2.4) 951 8 (0.8)
Total 2084 2043 44 (2.2) 1997 16 (0.8)
Control clusters
Burkina Faso 576 (457) 563 21 (3.7) 527 5 (0.9)
Ghana 591 (372) 591 8 (1.4) 573 10 (1.7)
Uganda 965 (512) 959 37 (3.9) 918 9 (1.0)
Total 2132 2113 66 (3.1) 2018 24 (1.2)
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by local treatment practices. It is possible that local antibiotic
prescription practices influenced behavior in the intervention
clusters. Vialle-Valentin and colleagues62 have reported higher
antibiotic use among under-five children in Ghana compared
with other countries including Uganda.
The study was conducted in areas with microscopic malaria
prevalence ranging between 54% and 80%. Cost-effectiveness
of the integrated package compared with presumptive malaria
treatment may be lower in areas with high rather than low
malaria transmission, if judged only by savings in anti-malarial
treatments. However, the WHO now recommends that all
suspected cases of malaria be confirmed with a diagnostic test
before treatment9 in all settings; furthermore, the development
of an integrated package fitting all epidemiologic settings,
regardless of the relative prevalence of malaria and pneumo-
nia, has obvious advantages in terms of translation into policy.
It is also possible that the overuse of medicines may be higher
in settings with lower malaria prevalence, in which many of
the RDTs would be negative. It will be important to explore
this issue further in these lower transmission settings.
The primary endpoint of our study was fever clearance 3 days
from initiation of treatment. One might expect a higher pro-
portion of children with fever to be afebrile after a few days
if treated more rationally, with different drugs based on the
results of diagnostic tests. Consistently across the study sites,
over 96% of the children were afebrile at the follow-up visits
in both intervention and control arms. Although a smaller
proportion of children in the intervention arm remained
febrile at Days 3 and 7 compared with the control arm, the
numbers of such children were small and the difference
observed could be caused by chance. This result is not easy to
interpret. One possibility is that the frequency of minor, self-
limiting viral infections as the cause of fevers was high, and
diluted the effect of specific anti-malarial and antibacterial
treatment. Furthermore, in a context of high parasitemia, it is
possible that antibiotics might not have a measurable effect
on fever clearance. Our findings are consistent with those
from a study in Zambia25 that found no evidence that the risk
of persistence of fever differed in intervention and control
clusters after 5 and 7 days of treatment. Adding cough/
difficulty breathing to our treatment algorithm would not have
altered this because most under-five children who needed an
antibiotic received one in the intervention arm.
The subgroup analysis that was conducted suggests that the
use of antibiotics in the control arm in Ghana may have
diluted the effect of the intervention, as there was some evi-
dence of an effect of the intervention on fever clearance when
data from only Burkina Faso and Uganda were used. How-
ever, visual inspection of the data from these two countries
does not suggest a large difference in fever clearance rates at
Day 3 in the intervention compared with the control arm.
Other aspects of feasibility, and acceptability of the
approach based on the diagnostic and treatment package was
assessed in all sites and will be reported in detail elsewhere.
Overall, the CHWs were found to be able to perform their
tasks satisfactorily, including RDTs for malaria and respira-
tory rate counting. A study in Uganda found that when RDT
results and RR were double-checked by laboratory techni-
cians and pediatricians there was a concordance rate of 100%
for RDTs and 93% for RR.19 The acceptability of CHWs
performing RDTs and RR counting was also high among
communities, CHWs, and health staff. The majority of inter-
viewed community members were satisfied with CHWs treat-
ing children according to the package.19
Though the study was not designed to evaluate RDT per-
formance, the positivity rates for microscopy were consis-
tently lower than those for RDTs across the three sites. This
may be explained by the fact that all three RDTs used HRP2
as the target antigen, which can persist in the blood stream
after parasite clearance,63–67 suggesting that some positive
RDTs were indicative of past rather than current infection.
The choice of which RDT to use was made for one of the fol-
lowing reasons: availability, resistance to high storage temper-
ature (40°C), delivery time, and national policy. Burkina Faso
received their supply from TDR as their original supplier failed
to deliver. The RDTs used were FirstSign in Burkina Faso,
Paracheck pf in Ghana, and ICT in Uganda. It should also be
noted that the RDTs were selected before the publication of
“Malaria Rapid Diagnostic Test Performance – Results of
WHO product testing of malaria RDTs Round 2”40 in which
RDT performance was recorded for 67 RDTs. The ranking of
the PDS for the RDTs was 28 for ICT, 49 for Paracheck, and
59 for First Sign,40 indicating that none really achieved a high
combined measure positivity rate, along with inter-test and
inter-lot consistency, although their PDSs were above 70/100.
The study shows that an iCCM approach based on the use
of diagnostics and medicines for malaria and pneumonia by
CHWs improves the rational use of anti-malarial drugs, and
may reduce the inappropriate use of antibiotics at the com-
munity level in settings where they are already available.
Fever clearance was very high in both intervention and con-
trol arms at both Day 3 and Day 7 and when all three coun-
tries were included in the analysis there was no clear evidence
of a clinical benefit of the intervention. These findings add to
the evidence base for iCCM as a public health strategy.
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